Scarica l'app Stockscreener
91.65
2.17%
1.95
Pre-mercato:
91.58
-0.07
-0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Medtronic Plc Borsa (MDT) Ultime notizie
What drives Medtronic plc stock priceExplosive capital appreciation - Autocar Professional
Medtronic plc Stock Analysis and ForecastDynamic growth stocks - Autocar Professional
Is Medtronic plc a good long term investmentJaw-dropping returns - jammulinksnews.com
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know - Nasdaq
What analysts say about Medtronic plc stockTurbocharged investment results - jammulinksnews.com
Medtronic gets EU nod for MiniMed 780G System - MSN
Medtronic’s (MDT) Role in Medical Devices: A Unique Fit for Halal Portfolios - MSN
Published on: 2025-07-22 10:22:55 - jammulinksnews.com
Medtronic (MDT): A Shariah-Compliant Powerhouse in the Evolving Medical Device Sector - AInvest
Medtronic MiniMed 780G wins CE mark for type 2 diabetes, young children - MassDevice
Court Nixes Jury Award Over Medtronic's Heart Valve Infringement ClaimMedtronic (NYSE:MDT) - Benzinga
Medtronic gets EU nod for MiniMed 780G System (MDT:NYSE) - Seeking Alpha
Medtronic (MDT) Expands MiniMed 780G System Indications with Eur - GuruFocus
Medtronic expands MiniMed 780G system indications across Europe - Investing.com Australia
Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes - Medtronic
10 Magnificent S&P 500 Dividend Stocks Down Over 10% to Buy and Hold Forever - The Motley Fool
Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict - MassDevice
Fed. Circ. Frees Medtronic From $125M Patent Judgment - Law360
Medtronic wins appeal to avoid $106.5M patent verdict (MDT:NYSE) - Seeking Alpha
Medtronic wins US appeal to overturn $106.5 mln heart-valve patent verdict - Reuters
Breaking Barriers: Medtronic and Zverev Unite - Il Messaggero
Medtronic’s SWOT analysis: renal denervation, diabetes spin-off to drive stock - Investing.com
Medtronic enrolls first patient in study for Onyx liquid embolic system - MassDevice
Analyst Expectations For Medtronic's Future - Benzinga
Got Their Backs: How Medtronic Brings Spine Surgeries to Kids - Yahoo Finance
Medtronic gets CE mark for robot-driven vessel-sealing device - MedTech Dive
Baird Adjusts Medtronic Price Target to $94 From $92, Maintains Neutral Rating - MarketScreener
Morgan Stanley Adjusts Medtronic Price Target to $107 From $98, Maintains Overweight Rating - MarketScreener
Medtronic : first in the U.S. to offer 400 cm 0.018” peripheral guidewire for transradial access - MarketScreener
Medtronic, Renal Denervation, and the Power of Persistence - Medical Device and Diagnostic industry
Medtronic (MDT) Price Target Raised by Morgan Stanley | MDT Stoc - GuruFocus
Medtronic shaping future of surgery, secures CE Mark for LigaSure™ technology on Hugo™ robotic-assisted surgery system - Medtronic
Medtronic (MDT) Experiences Increased Bearish Options Activity | MDT Stock News - GuruFocus
Prostate Care Market Report 2025-2031 | Medtronic, Johnson & Johnson, Boston Scientific, and Abbott Laboratories Dominate through Product Innovations, Clinical Trials, M&As, and Strategic Partnerships - Yahoo Finance
Medtronic Stock Is Climbing Friday: What's Going On?Medtronic (NYSE:MDT) - Benzinga
Medtronic (MDT) Stock Insights and Investment Tools | MDT Stock News - GuruFocus
Medtronic (MDT) Gains from CMS Proposal on Renal Denervation Coverage | MDT Stock News - GuruFocus
Medtronic Says Centers for Medicare & Medicaid Services Proposes National Coverage for Blood Pressure Treatment Device - MarketScreener
Unusual Options Activity Noticed for Medtronic (MDT) | MDT Stock News - GuruFocus
Medtronic (MDT) Set for Growth with Proposed Coverage for Renal Denervation | MDT Stock News - GuruFocus
Medtronic (MDT) Gains Following Medicare's Review of New Hypertension Technology | MDT Stock News - GuruFocus
William Blair reiterates Market Perform rating on Medtronic stock after CMS proposal - Investing.com
Medtronic, Recor praise new CMS coverage for renal denervation - MassDevice
Medtronic : issues statement on the U.S. Centers for Medicare & Medicaid Services proposed National Coverage Determination for Symplicity Spyral™ renal denervation (RDN) system - MarketScreener
Citi Analyst Boosts Medtronic (MDT) Price Target to $99 | MDT Stock News - GuruFocus
Needham Keeps Hold Rating on Medtronic (MDT) Amid Spin-Off News - MSN
2.02%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):